New hope for advanced liver cancer: drug combo shows promise in early trial
NCT ID NCT05644379
First seen Feb 11, 2026 · Last updated Jun 17, 2026 · Updated 20 times
Summary
This early-phase study tests whether combining two drugs, cadonilimab and regorafenib, can help people with advanced liver cancer whose disease has worsened after at least one prior treatment. About 30 adults will receive the combination to see if tumors shrink and how safe the treatment is. The goal is to control the cancer, not cure it, and participants will need ongoing monitoring.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA THAT HAS FAILED AT LEAST ONE PRIOR SYSTEMIC THERAPY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Tianjin Cancer Hospital Airport Hospital
Tianjin, Tianjin Municipality, 300308, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.